Cargando…

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Maio, Massimo, Daniele, Gennaro, Piccirillo, Maria Carmela, Giordano, Pasqualina, Signoriello, Giuseppe, Daniele, Bruno, Perrone, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712698/ https://www.ncbi.nlm.nih.gov/pubmed/24213324 http://dx.doi.org/10.3390/cancers4020549

Ejemplares similares

Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma
por: Gallo, Ciro, et al.
Publicado: (2006)

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation
por: Minoux, Kate, et al.
Publicado: (2022)

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Time Spent for Activation of Non-Profit Studies in Oncology in Italy
por: De Feo, Gianfranco, et al.
Publicado: (2010)

Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients
por: Signoriello, Simona, et al.
Publicado: (2012)

Maintenance of Species Boundaries Despite Ongoing Gene Flow in Ragworts
por: Osborne, Owen G., et al.
Publicado: (2016)

Awaiting the “catharsis”
por: Yfantopoulos, John
Publicado: (2020)

Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
por: GADALETA-CALDAROLA, GENNARO, et al.
Publicado: (2014)

Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes
por: Di Martino, Marcello, et al.
Publicado: (2022)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Long-Awaited Results from Long Island Study
por: Holzman, DC
Publicado: (2003)

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Rewards await the far-cited
por: O'keefe, Brendan
Publicado: (2005)

Grid awaits secrets of universe
Publicado: (2008)

Grid awaits secrets of universe
Publicado: (2008)

Grid awaits secrets of universe
Publicado: (2008)

Grid awaits secrets of universe
Publicado: (2008)

Grid awaits secrets of universe
Publicado: (2008)

Grid awaits secrets of universe
Publicado: (2008)

Stabilization of the critically ill neonate awaiting transport
por: Gente, Maurizio, et al.
Publicado: (2015)

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial
por: Nuzzo, Francesco, et al.
Publicado: (2011)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
por: Federico, Piera, et al.
Publicado: (2020)

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence
por: Sinakos, Emmanouil, et al.
Publicado: (2011)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma
por: Briggs, Andrew, et al.
Publicado: (2020)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Awaiting the replacement No. 6 PS magnet
por: Maximilien Brice
Publicado: (2003)

Commentary: In the aftermath, what awaits us?
por: Klapper, Jacob A.
Publicado: (2022)

A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
por: Chiodini, Paolo, et al.
Publicado: (2020)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

The Management of Ruptured Abdominal Aortic Aneurysms: An Ongoing Challenge
por: Troisi, Nicola, et al.
Publicado: (2023)

MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
por: Alsebaey, Ayman, et al.
Publicado: (2021)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_495vhvit2lgrs7o7pledort67v